Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Unternehmen & Branche
| Name | Centessa Pharmaceuticals plc |
|---|---|
| Ticker | CNTA |
| CIK | 0001847903 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | 152309100 |
|---|---|
| ISIN | US1523091007 |
| Typ | ADR |
| Marktkapitalisierung | 5,90 Mrd. USD |
| Beta | 1,26 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 15,000,000 | -197,532,000 | -1.46 | 687,495,000 | 526,863,000 |
| 2025-09-30 | 10-Q | 0 | -54,891,000 | -0.41 | 448,300,000 | 301,574,000 |
| 2025-06-30 | 10-Q | 0 | -50,343,000 | -0.38 | 492,127,000 | 344,919,000 |
| 2025-03-31 | 10-Q | 15,000,000 | -26,135,000 | -0.20 | 527,845,000 | 386,247,000 |
| 2024-12-31 | 10-K | 0 | -235,757,000 | -2.06 | 576,798,000 | 401,545,000 |
| 2024-09-30 | 10-Q | 0 | -42,566,000 | -0.37 | 609,715,000 | 499,137,000 |
| 2024-06-30 | 10-Q | 0 | -43,816,000 | -0.40 | 398,845,000 | 286,965,000 |
| 2024-03-31 | 10-Q | 0 | -38,046,000 | -0.38 | 328,171,000 | 215,163,000 |
| 2023-12-31 | 10-K | 6,853,000 | -151,085,000 | -1.57 | 360,246,000 | 236,244,000 |
| 2023-09-30 | 10-Q | -38,648,000 | -0.40 | 377,364,000 | 259,390,000 | |
| 2023-06-30 | 10-Q | -24,886,000 | -0.26 | 392,921,000 | 276,606,000 | |
| 2023-03-31 | 10-Q | -50,714,000 | -0.53 | 403,860,000 | 293,261,000 | |
| 2022-12-31 | 10-K | 0 | -216,207,000 | -2.31 | 444,307,000 | 336,169,000 |
| 2022-09-30 | 10-Q | -53,875,000 | -0.57 | 479,355,000 | 372,921,000 | |
| 2022-06-30 | 10-Q | -64,661,000 | -0.69 | 521,051,000 | 420,039,000 | |
| 2022-03-31 | 10-Q | -54,498,000 | -0.60 | 582,188,000 | 480,151,000 | |
| 2021-12-31 | 10-K | -381,071,000 | -5.07 | 629,635,000 | 491,554,000 | |
| 2021-09-30 | 10-Q | -40,155,000 | -0.45 | 612,207,000 | 549,133,000 | |
| 2021-06-30 | 10-Q | -41,451,000 | -0.65 | 643,757,000 | 585,642,000 | |
| 2021-03-31 | 10-Q | -238,691,000 | -4.97 | 278,634,000 |
Fondsaktivität (Vorquartalsvergleich)
| Fonds | Aktuell (Stk) | Vorquartal (Stk) | Veränderung (Stk) | Wert (USD) | Status | Δ | Trend |
|---|---|---|---|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 19,963,157 | 19,963,157 | 0 | 792,936,596 | Unverändert | 0,0% | |
| FMR LLC | 8,961,939 | 0 | 8,961,939 | 224,138,094 | Neu | +100,0% | |
| FARALLON CAPITAL MANAGEMENT LLC | 5,377,068 | 0 | 5,377,068 | 134,480,471 | Neu | +100,0% | |
| JANUS HENDERSON GROUP PLC | 4,093,608 | 0 | 4,093,608 | 102,393,318 | Neu | +100,0% | |
| Siren, L.L.C. | 4,027,517 | 0 | 4,027,517 | 100,728,200 | Neu | +100,0% | |
| PERCEPTIVE ADVISORS LLC | 2,917,634 | 0 | 2,917,634 | 72,970,026 | Neu | +100,0% | |
| FRANKLIN RESOURCES INC | 2,368,381 | 0 | 2,368,381 | 59,233,201 | Neu | +100,0% | |
| Deep Track Capital, LP | 2,000,000 | 0 | 2,000,000 | 50,020,000 | Neu | +100,0% | |
| MILLENNIUM MANAGEMENT LLC | 1,870,671 | 0 | 1,870,671 | 46,785,482 | Neu | +100,0% | |
| RTW INVESTMENTS, LP | 1,790,837 | 0 | 1,790,837 | 44,788,833 | Neu | +100,0% | |
| MAVERICK CAPITAL LTD | 1,643,724 | 0 | 1,643,724 | 41,109,537 | Neu | +100,0% | |
| ALPINE ASSOCIATES MANAGEMENT INC. | 865,500 | 0 | 865,500 | 34,377,660 | Neu | +100,0% | |
| Foresite Capital Management VI LLC | 1,364,019 | 0 | 1,364,019 | 34,114,115 | Neu | +100,0% | |
| Cormorant Asset Management, LP | 1,325,000 | 0 | 1,325,000 | 33,138,250 | Neu | +100,0% | |
| Capital World Investors | 1,158,699 | 0 | 1,158,699 | 28,979,062 | Neu | +100,0% | |
| AMERICAN CENTURY COMPANIES INC | 1,129,758 | 0 | 1,129,758 | 28,255,300 | Neu | +100,0% | |
| MORGAN STANLEY | 1,109,098 | 0 | 1,109,098 | 27,738,558 | Neu | +100,0% | |
| Commodore Capital LP | 1,000,000 | 0 | 1,000,000 | 25,010,000 | Neu | +100,0% | |
| BANK OF AMERICA CORP /DE/ | 949,544 | 0 | 949,544 | 23,748,095 | Neu | +100,0% | |
| D. E. Shaw & Co., Inc. | 831,636 | 0 | 831,636 | 20,799,216 | Neu | +100,0% | |
| GOLDMAN SACHS GROUP INC | 779,001 | 0 | 779,001 | 19,482,815 | Neu | +100,0% | |
| Octagon Capital Advisors LP | 750,000 | 0 | 750,000 | 18,757,500 | Neu | +100,0% | |
| BAKER BROS. ADVISORS LP | 670,751 | 0 | 670,751 | 16,775,483 | Neu | +100,0% | |
| BlackRock, Inc. | 592,604 | 0 | 592,604 | 14,821,027 | Neu | +100,0% | |
| PFM Health Sciences, LP | 591,601 | 0 | 591,601 | 14,795,941 | Neu | +100,0% | |
| 5AM Venture Management, LLC | 580,945 | 0 | 580,945 | 14,529,434 | Neu | +100,0% | |
| CITADEL ADVISORS LLC | 579,862 | 0 | 579,862 | 14,502,348 | Neu | +100,0% | |
| JANE STREET GROUP, LLC | 576,704 | 0 | 576,704 | 14,423,367 | Neu | +100,0% | |
| UBS Group AG | 359,939 | 572,818 | -212,879 | 14,296,778 | Reduziert | -37,2% | |
| Walleye Capital LLC | 441,160 | 0 | 441,160 | 11,033,412 | Neu | +100,0% | |
| Qube Research & Technologies Ltd | 378,740 | 0 | 378,740 | 9,472,287 | Neu | +100,0% | |
| ROYCE & ASSOCIATES LP | 362,873 | 0 | 362,873 | 9,075,454 | Neu | +100,0% | |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | 348,279 | 0 | 348,279 | 8,710,458 | Neu | +100,0% | |
| Saturn V Capital Management LP | 282,692 | 0 | 282,692 | 7,070,127 | Neu | +100,0% | |
| AMERIPRISE FINANCIAL INC | 280,120 | 0 | 280,120 | 7,005,800 | Neu | +100,0% | |
| RENAISSANCE TECHNOLOGIES LLC | 279,300 | 0 | 279,300 | 6,985,293 | Neu | +100,0% | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 268,763 | 0 | 268,763 | 6,721,763 | Neu | +100,0% | |
| Nantahala Capital Management, LLC | 254,803 | 0 | 254,803 | 6,372,623 | Neu | +100,0% | |
| WCM INVESTMENT MANAGEMENT, LLC | 257,190 | 0 | 257,190 | 6,362,881 | Neu | +100,0% | |
| HighMark Wealth Management LLC | 236,785 | 0 | 236,785 | 5,921,992 | Neu | +100,0% | |
| MARSHALL WACE, LLP | 216,130 | 0 | 216,130 | 5,405,411 | Neu | +100,0% | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | 211,253 | 0 | 211,253 | 5,230,170 | Neu | +100,0% | |
| Caption Management, LLC | 172,900 | 0 | 172,900 | 4,324,229 | Neu | +100,0% | |
| Legal & General Group Plc | 110,207 | 105,427 | 4,780 | 4,321,502 | Aufgestockt | +4,5% | |
| FRED ALGER MANAGEMENT, LLC | 162,147 | 0 | 162,147 | 4,055,296 | Neu | +100,0% | |
| DEUTSCHE BANK AG\ | 156,205 | 0 | 156,205 | 3,906,687 | Neu | +100,0% | |
| PLATINUM INVESTMENT MANAGEMENT LTD | 155,101 | 0 | 155,101 | 3,879,076 | Neu | +100,0% | |
| Y-Intercept (Hong Kong) Ltd | 96,367 | 11,441 | 84,926 | 3,827,697 | Aufgestockt | +742,3% | |
| Trexquant Investment LP | 146,523 | 0 | 146,523 | 3,664,540 | Neu | +100,0% | |
| TUDOR INVESTMENT CORP ET AL | 121,810 | 0 | 121,810 | 3,046,468 | Neu | +100,0% |
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-15 | HUSSAIN IQBAL J | Officer, General Counsel | Open Market Sale | -6,000 | 17.23 | -103,380.00 | -14,5% | |
| 2025-07-29 | Accardi Mario Alberto | Officer, President, Orexin Program | Open Market Sale | -8,322 | 15.23 | -126,750.72 | -17,8% | |
| 2025-07-25 | Weinhoff Gregory M | Officer, Chief Business Officer | Open Market Sale | -10,000 | 15.56 | -155,598.00 | -21,9% | |
| 2025-07-21 | SAHA SAURABH | Director, Officer, Chief Executive Officer | Open Market Sale | -55,000 | 15.92 | -875,600.00 | -123,0% | |
| 2025-07-15 | HUSSAIN IQBAL J | Officer, General Counsel | Open Market Sale | -6,000 | 14.93 | -89,566.80 | -12,6% | |
| 2025-06-25 | Weinhoff Gregory M | Officer, Chief Business Officer | Open Market Sale | -10,000 | 13.86 | -138,642.00 | -19,5% | |
| 2025-06-24 | HUSSAIN IQBAL J | Officer, General Counsel | Open Market Sale | -12,000 | 14.02 | -168,218.40 | -23,6% | |
| 2025-06-24 | Accardi Mario Alberto | Officer, President, Orexin Program | Open Market Sale | -15,000 | 14.00 | -210,000.00 | -29,5% | |
| 2025-06-20 | SAHA SAURABH | Director, Officer, Chief Executive Officer | Open Market Sale | -55,000 | 12.63 | -694,826.00 | -97,6% | |
| 2025-05-27 | Weinhoff Gregory M | Officer, Chief Business Officer | Open Market Sale | -10,000 | 12.82 | -128,225.00 | -18,0% | |
| 2025-05-20 | SAHA SAURABH | Director, Officer, Chief Executive Officer | Open Market Sale | -55,000 | 12.71 | -699,110.50 | -98,2% | |
| 2025-05-16 | GOYAL ARJUN | Director | Open Market Purchase | 417,646 | 12.73 | 5,315,004.76 | +746,6% | |
| 2025-05-15 | GOYAL ARJUN | Director | Open Market Purchase | 44,939 | 12.24 | 550,237.61 | +77,3% |
Fail-to-Deliver (6 Monate)
| Datum | FTD-Menge | Kurs | Wert (USD) |
|---|---|---|---|
| 2026-04-14 | 5 | 39,57 | 198 |
| 2026-04-13 | 44 | 39,48 | 1.737 |
| 2026-04-08 | 211 | 39,55 | 8.345 |
| 2026-04-06 | 111 | 39,69 | 4.406 |
| 2026-04-02 | 221.240 | 39,86 | 8.818.626 |
| 2026-04-01 | 384.340 | 39,72 | 15.265.985 |
| 2026-03-25 | 13.751 | 27,89 | 383.515 |
| 2026-03-24 | 12.833 | 25,94 | 332.888 |
| 2026-03-23 | 1.240 | 27,06 | 33.554 |
| 2026-03-18 | 200 | 28,95 | 5.790 |
| 2026-03-17 | 7.866 | 28,29 | 222.529 |
| 2026-03-16 | 2.830 | 26,33 | 74.514 |
| 2026-03-12 | 14.878 | 28,22 | 419.857 |
| 2026-03-10 | 36.906 | 26,09 | 962.878 |
| 2026-03-04 | 168 | 26,20 | 4.402 |
| 2026-03-03 | 4.326 | 26,51 | 114.682 |
| 2026-02-23 | 2.130 | 24,50 | 52.185 |
Top-Fondshalter
Stand: 31.03.2026
| Fonds | Anteile | Wert (USD) | Anteil (%) |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 19,963,157 | 792,936,596 | 92.53 |
| ALPINE ASSOCIATES MANAGEMENT INC. | 865,500 | 34,377,660 | 4.01 |
| UBS Group AG | 359,939 | 14,296,778 | 1.67 |
| Legal & General Group Plc | 110,207 | 4,321,502 | 0.50 |
| Y-Intercept (Hong Kong) Ltd | 96,367 | 3,827,697 | 0.45 |
| Pictet Asset Management Holding SA | 96,910 | 2,672,778 | 0.31 |
| Russell Investments Group, Ltd. | 38,812 | 1,541,612 | 0.18 |
| Candriam S.C.A. | 36,254 | 1,440,009 | 0.17 |
| China Universal Asset Management Co., Ltd. | 21,225 | 843,057 | 0.10 |
| Brooklyn Investment Group | 7,443 | 295,636 | 0.03 |
| GAMMA Investing LLC | 3,980 | 158,086 | 0.02 |
| GF FUND MANAGEMENT CO. LTD. | 2,166 | 86,034 | 0.01 |
| Bayforest Capital Ltd | 1,947 | 77,335 | 0.01 |
| ADIRONDACK TRUST CO | 925 | 36,741 | 0.00 |
| NBC SECURITIES, INC. | 60 | 2,383 | 0.00 |
| Aspect Partners, LLC | 30 | 1,192 | 0.00 |
| SJS Investment Consulting Inc. | 22 | 874 | 0.00 |
| Farther Finance Advisors, LLC | 20 | 797 | 0.00 |
| SG Americas Securities, LLC | 3,081 | 122 | 0.00 |